Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 4Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasm, Residual 1Liposarcoma 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid and Hematological TP53wt Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 7Ipilimumab 7Nivolumab 5Melphalan 5Dacarbazine 3tebentafusp 2sotrastaurin 2binimetinib 2Pemetrexed 2Crizotinib 2ADI PEG20 2utomilumab 1trametinib 1tocilizumab 1siremadlin 1ruxolitinib 1relatlimab 1obinutuzumab 1fludarabine phosphate 1fludarabine 1cemiplimab 1avelumab 1Watchful Waiting 1Toll-Like Receptor 1 1Standard of Care 1Solutions 1Rose Bengal 1Protein Kinase C 1Polyethylene Glycols 1Opdualag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uveal Melanoma × siremadlin × Clear all
NCT02601378 2022-09-29

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Novartis

Phase 1 Terminated
107 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡